Table 3.
Optical Coherence Tomography Evaluation at 14 and 28-day
| NA (mm2) | P | CSR% | P | ||
|---|---|---|---|---|---|
| 14 day | |||||
| BMS (n = 8) | 1.46 (1.35,1.69) | 0.708 | 37.67 (26.74,50.65) | 0.011 | |
| PrES (n = 9) | 1.56 (1.35,1.88) | 53.24 (38.99,81.05) | |||
| SES (n = 7) | 1.52 (1.16,1.61) | 20.27 (13.49,25.95) | |||
| DDES(n = 8) | 1.38 (1.34,1.56) | 40.06 (14.12,50.16) | |||
| 28 day | |||||
| BMS (n = 7) | 2.57 (1.75,2.98) | 0.300 | 93.64 (89.07,97.79) | 0.644 | |
| PrES (n = 7) | 2.23 (1.57,3.15) | 92.77 (50.00,98.23) | |||
| SES (n = 7) | 1.91 (1.49,2.30) | 85.15 (84.94,100.00) | |||
| DDES(n = 6) | 1.68 (1.54,2.40) | 88.22 (64.24,94.56) | |||
NA Neointimal Area, CSR% Ratio of Covered Struts, BMS Bare-Metal Stents, PrES Probucol-Eluting Stents, SES Sirolimus-Eluting Stents, DDES Dual Drug-Eluting Stents